Skip to main content

Market Overview

Neon Therapeutics Shares Higher After Positive Cancer Vaccine Study

Neon Therapeutics Shares Higher After Positive Cancer Vaccine Study

Neon Therapeutics (NASDAQ: NTGN) shares are trading higher after the company announced its personal neoantigen vaccine study demonstrated prolonged progression-free survival in advanced or metastatic melanoma, non-small cell lung and bladder cancers.

“Data demonstrate a promising new approach in the field of cancer immunotherapy with the potential to further broaden and extend the benefits of checkpoint inhibitor treatment to improve patient outcomes in multiple cancer settings,” said Patrick Ott, Clinical Director, Melanoma Center, Center for Immuno-Oncology at the Dana-Farber Cancer Institute and a lead investigator in the NT-001 trial.

“With these NT-001 results, we are observing consistent prolongation of progression-free survival across all three tumor types compared with historical checkpoint inhibitor monotherapy studies involving patients with similar baseline characteristics. This is an exciting step in establishing the potential of neoantigen-based therapies as a vital component of the cancer treatment landscape."

Neon Therapeutics shares traded higher by 7.6% at $4.65 in Monday's pre-market session. The stock has a 52-week high of $13.00 and a 52-week low of $4.18.

Related Links:

Zosano Pharma Presents Positive Migraine-ACT Results

Callon Petroleum To Acquire Carrizo In All Stock Deal


Related Articles (NTGN)

View Comments and Join the Discussion!

Posted-In: News Health Care General

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at